A Phase i Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer

Investigational New Drugs

Volumn 31, Issue 5, 2013, Pages 1244-1250

  Halmos, Balazs ^a,b   Jia, Yuxia ^b   Bokar, Joseph A ^a   Fu, Pingfu ^a   Adelstein, David J ^c   Juergens, Rosalyn ^d   Rodal, Mary Beth ^a   Dowlati, Afshin ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b Department of Medicine   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Docetaxel; Gastroesophageal cancer; Oxaliplatin; Phase I; Vandetanib

Indexed keywords

DOCETAXEL; OXALIPLATIN; VANDETANIB;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; GASTROESOPHAGEAL CARCINOMA; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; LEUKOCYTE; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPHIL; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMACH CARCINOMA; THROMBOCYTE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TAXOIDS;

EID: 84884819988     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9945-8     Document Type: Article

References (37)

1. American Cancer Society: Cancer Facts and Figures (2012)
2. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349(23):2241-2252
3. NCCN Clinical Practice guidelines in oncology. Esophageal cancer (2011)
4. Ajani JA et al (2007) Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25(22):3205-3209
5. Ajani JA et al (2007) Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25(22):3210-3216
6. Tamura S et al (2012) Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res 32(4):1403-1408
7. Chau I, Ashley S, Cunningham D (2009) Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol 27(19):e3-e4
8. Richards D et al (2008) Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol 19(1):104-108
9. Evans TR et al (2002) A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 13(9):1469-1478
10. Evans D et al (2007) A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. Am J Clin Oncol 30(4):346-349
11. Hwang JJ, S.M, Moore DJ, McGreivy J, Park S, Zamboni WC, Marshall JL (2005) A Phase I and Pharmacokinetic (PK) Study of Docetaxel (DOC) and Oxaliplatin (OX). J Clin Oncol. 23(16s): p. suppl; abstr 2105
12. Gibson MK et al (2003) Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 9(17):6461-6468
13. Walsh TN, Grannell M, Mansoor S (2002) Predictive factors for success of neo-Adjuvant therapy in upper gastrointestinal cancer. J Gastroenterol Hepatol 17(Suppl):S172-S175
14. Okines A, Cunningham D, Chau I (2011) Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 8(8):492-503
15. Okines AF, Reynolds AR, Cunningham D (2011) Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist 16(6):844-858
16. Bang YJ et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687-697
17. Shah MA et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 29(7):868-74
18. Rodriguez CP et al. Single-Arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. Head Neck. 34(11):1517-23
19. Dragovich T et al (2006) Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 24(30):4922-4927
20. Ilson DH (2008) Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res 2(2):85-92
21. Adelstein DJ et al. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Invest New Drugs. 30(4):1684-9
22. David Ferry EA (2012) Phase III multi-centre, randomised, double-blind, placebo-controlled parallel arm trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy on behalf of the COG (Cancer Oesophagus Gefitinib) Collaborative Group. European Society for Medical Oncology (ESMO)
23. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):967-974
24. Ohtsu A et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29(30):3968-3976
25. Morelli MP et al (2006) Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 208(2):344-353
26. Heymach JV et al (2007) Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25(27):4270-4277
27. Tamura T et al (2006) A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 1(9):1002-1009
28. Robinson BG et al (2010) Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2664-2671
29. Wells SA et al (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary thyroid cancer. J Clin Oncol 28(5)767-72
30. Wells SA Jr et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2):134-141
31. Cohen MS, Hussain HB, Moley JF (2002) Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132(6):960-966, discussion 966-7
32. Santoro M, Carlomagno F (2006) Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2(1):42-52
33. Kouroussis C et al (2003) A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 23(1B):785-791
34. Schuette W et al (2005) Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23(33):8389-8395
35. Heymach JV et al (2008) Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26(33):5407-5415
36. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457-481
37. Herbst RS et al (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11(7):619-626